You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlmesartan
Accession NumberDB00275  (APRD00223)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOlmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.
Structure
Thumb
Synonyms
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
External Identifiers
  • DE-092
  • RNH-6270
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenicarTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2004-01-30Not applicableUs
BenicarTablet, film coated40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-22Not applicableUs
BenicarTablet, film coated20 mg/1OralDaiichi Sankyo, Inc.2002-04-25Not applicableUs
BenicarTablet, film coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralA S Medication Solutions2002-04-25Not applicableUs
BenicarTablet, film coated40 mg/1OralMed Health Pharma, LLC2012-02-02Not applicableUs
BenicarTablet, film coated20 mg/1OralCardinal Health2002-04-25Not applicableUs
BenicarTablet, film coated40 mg/1OralDaiichi Sankyo, Inc.2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-22Not applicableUs
BenicarTablet, film coated40 mg/1Oralbryant ranch prepack2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-10-042016-04-05Us
BenicarTablet, film coated40 mg/1OralCardinal Health2002-04-25Not applicableUs
BenicarTablet, film coated5 mg/1OralCarilion Materials Management2002-04-25Not applicableUs
BenicarTablet, film coated5 mg/1OralMed Health Pharma, LLC2012-02-02Not applicableUs
BenicarTablet, film coated20 mg/1Oralbryant ranch prepack2002-04-25Not applicableUs
BenicarTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2003-08-06Not applicableUs
BenicarTablet, film coated20 mg/1OralCardinal Health2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralA S Medication Solutions2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralMed Health Pharma, LLC2012-02-02Not applicableUs
BenicarTablet, film coated5 mg/1OralDaiichi Sankyo, Inc.2002-04-25Not applicableUs
Olmesartan MedoxomilTablet, film coated40 mg/1OralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated5 mg/1OralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated20 mg/1OralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
OlmetecTablet20 mgOralMerck Canada Inc2008-12-22Not applicableCanada
OlmetecTablet40 mgOralMerck Canada Inc2008-12-22Not applicableCanada
OlmetecTablet5 mgOralMerck Canada IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Olmesartan MedoxomilTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated40 mg/1OralMylan Institutional Inc.2016-11-10Not applicableUs
Olmesartan MedoxomilTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated40 mg/1OralMylan Pharmaceuticals Inc.2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated20 mg/1OralMylan Institutional Inc.2016-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErastapexNot Available
GolmeNot Available
OlmetecNot Available
WinBPNot Available
Brand mixtures
NameLabellerIngredients
Amlodipine and Olmesartan MedoxomilMacleods Pharmaceuticals Limited
Amlodipine Besylate and Olmesartan MedoxomilAjanta Pharma Limited
AzorPhysicians Total Care, Inc.
Benicar HctLake Erie Medical & Surgical Supply DBA Quality Care Products LLC
Olmesartan Medoxmil and HydrochlorothiazideMylan Pharmaceuticals Inc.
Olmesartan Medoxomil / Amlodipine Besylate / HydrochlorothiazidePar Pharmaceutical, Inc.
Olmesartan Medoxomil and HydrochlorothiazideSun Pharmaceutical Industries, Inc.
Olmesartan Medoxomil, Amlodipine and HydrochlorothiazideSun Pharmaceutical Industries, Inc.
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/25 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/25 mgTorrent Pharmaceuticals Limited
Olmetec PlusMerck Canada Inc
TribenzorDaiichi Sankyo, Inc.
Salts
Name/CASStructureProperties
Olmesartan medoxomil
144689-63-4
Thumb
  • InChI Key: UQGKUQLKSCSZGY-UHFFFAOYSA-N
  • Monoisotopic Mass: 558.22268271
  • Average Mass: 558.595
DBSALT001815
Categories
UNII8W1IQP3U10
CAS number144689-24-7
WeightAverage: 446.5016
Monoisotopic: 446.206638728
Chemical FormulaC24H26N6O3
InChI KeyVTRAEEWXHOVJFV-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid
SMILES
CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications
PharmacodynamicsOlmesartan is a specific angiotensin II type 1 (AT1) receptor antagonist, which blocks the blood pressure increasing effects of angiotensin II via the renin-angiotensin-aldosterone system (RAAS). During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and AT2. AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionOlmesartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Olmesartan is selective for AT1 and has a 12,500 times greater affinity for AT1 than the AT2 receptor. Also unlike the well-known ARB losartan, olmesartan does not have an active metabolite or possess uricosuric effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionBioavailability is about 26%. Food does not affect the bioavailability of olmesartan.
Volume of distribution

The volume of distribution is 17 L and olmesartan poorly crosses the blood brain barrier.

Protein bindingHighly bound to plasma proteins (99%) and does not penetrate red blood cells.
Metabolism

Olmesartan is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. There is virtually no further metabolism of olmesartan.

Route of eliminationOlmesartan is elminated unchanged in the urine (35% to 50%) and the remainder in the feces.
Half lifeThe half life is approximately 13 hours.
Clearance
  • Total plasma cl=1.3 L/h
  • Renal cl=0.6 L/h
ToxicityThe main symptoms of overdose include low blood pressure and fast heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Olmesartan Action PathwayDrug actionSMP00163
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Olmesartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Olmesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
AlprenololOlmesartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanOlmesartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineOlmesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Olmesartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Olmesartan.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Olmesartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Olmesartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Olmesartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Olmesartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Olmesartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benoxaprofen.Withdrawn
BepridilOlmesartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Olmesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Olmesartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Betulinic Acid.Investigational
BimatoprostOlmesartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bortezomib.Approved, Investigational
BosentanOlmesartan may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Olmesartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bupivacaine.Approved, Investigational
BupranololOlmesartan may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Olmesartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Olmesartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Celecoxib.Approved, Investigational
CeliprololOlmesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Olmesartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorthalidone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilnidipine.Approved
CiprofloxacinOlmesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clozapine.Approved
ColesevelamThe serum concentration of Olmesartan can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Conivaptan.Approved, Investigational
CryptenamineOlmesartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Olmesartan is combined with Curcumin.Investigational
CyclosporineOlmesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideOlmesartan may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Olmesartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Olmesartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Olmesartan.Investigational
DebrisoquinOlmesartan may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineOlmesartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Olmesartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenamide.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diflunisal.Approved
DihydralazineOlmesartan may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dipyridamole.Approved
DorzolamideOlmesartan may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Doxazosin.Approved
DrospirenoneOlmesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Droxicam.Approved
DuloxetineOlmesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Olmesartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ebselen.Investigational
EfonidipineOlmesartan may increase the hypotensive activities of Efonidipine.Approved
EltrombopagThe serum concentration of Olmesartan can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Olmesartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Olmesartan.Approved
EpoprostenolOlmesartan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Olmesartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Olmesartan is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenbufen.Approved
FenoldopamOlmesartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Furosemide.Approved, Vet Approved
GuanabenzOlmesartan may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Olmesartan.Approved
GuanethidineOlmesartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
HexamethoniumOlmesartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Olmesartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Olmesartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Olmesartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideOlmesartan may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Olmesartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Olmesartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indapamide.Approved
IndenololOlmesartan may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indoprofen.Withdrawn
IndoraminOlmesartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Olmesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Olmesartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Olmesartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Olmesartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Kebuzone.Experimental
KetanserinOlmesartan may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Labetalol.Approved
LacidipineOlmesartan may increase the hypotensive activities of Lacidipine.Approved
LatanoprostOlmesartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Leflunomide.Approved, Investigational
LercanidipineOlmesartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Levobupivacaine.Approved
LevodopaOlmesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olmesartan.Approved
LofexidineOlmesartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Losartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lumiracoxib.Approved, Investigational
MacitentanOlmesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate.Approved
ManidipineOlmesartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Olmesartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Olmesartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Olmesartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Olmesartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Olmesartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Olmesartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Olmesartan.Approved, Investigational
MetyrosineOlmesartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilOlmesartan may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Olmesartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Minoxidil.Approved
MizoribineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Olmesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Olmesartan.Approved
MorphineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Morphine.Approved, Investigational
MoxonidineOlmesartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Olmesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naftifine.Approved
NaftopidilOlmesartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Olmesartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Olmesartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Olmesartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Niflumic Acid.Approved
NiguldipineOlmesartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineOlmesartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nisoldipine.Approved
NitrendipineOlmesartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroprusside.Approved
ObinutuzumabOlmesartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Olmesartan.Withdrawn
OlopatadineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.Approved
OxprenololOlmesartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Olmesartan is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Olmesartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Olmesartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
PentoliniumOlmesartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Olmesartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Olmesartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Olmesartan.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Olmesartan.Approved
PhenoxybenzamineOlmesartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Olmesartan.Withdrawn
PhentolamineOlmesartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilOlmesartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Olmesartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Olmesartan.Withdrawn
PolythiazideOlmesartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propranolol.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Olmesartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Olmesartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Olmesartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Olmesartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olmesartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Olmesartan.Approved
RilmenidineOlmesartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Riociguat.Approved
RisperidoneOlmesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabOlmesartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Olmesartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salsalate.Approved
SaprisartanOlmesartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Olmesartan.Approved, Investigational, Vet Approved
SelexipagOlmesartan may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
SitaxentanOlmesartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Olmesartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Olmesartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin.Approved
TeriflunomideThe serum concentration of Olmesartan can be increased when it is combined with Teriflunomide.Approved
TerlipressinOlmesartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tiaprofenic acid.Approved
TiboloneOlmesartan may increase the hypotensive activities of Tibolone.Approved
TicrynafenOlmesartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Olmesartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.Approved
TolazolineOlmesartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Olmesartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Olmesartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Olmesartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Olmesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Olmesartan.Approved
TravoprostOlmesartan may increase the hypotensive activities of Travoprost.Approved
TreprostinilOlmesartan may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triamterene.Approved
TrichlormethiazideOlmesartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinOlmesartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanOlmesartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Olmesartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
UnoprostoneOlmesartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olmesartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Olmesartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.Approved
VinpocetineOlmesartan may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineOlmesartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Olmesartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zomepirac.Withdrawn
Food Interactions
  • Food does not affect the bioavailability of olmesartan.
References
Synthesis Reference

Lilach Hedvati, Gideon Pilarsky, “Preparation of olmesartan medoxomil.” U.S. Patent US20060069141, issued March 30, 2006.

US20060069141
General ReferencesNot Available
External Links
ATC CodesC09DA08C09DX03C09CA08C09DB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (179 KB)
MSDSDownload (58.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.8719
Caco-2 permeable-0.6865
P-glycoprotein substrateSubstrate0.7247
P-glycoprotein inhibitor INon-inhibitor0.5917
P-glycoprotein inhibitor IIInhibitor0.6029
Renal organic cation transporterNon-inhibitor0.807
CYP450 2C9 substrateNon-substrate0.7429
CYP450 2D6 substrateNon-substrate0.8602
CYP450 3A4 substrateNon-substrate0.5149
CYP450 1A2 substrateNon-inhibitor0.782
CYP450 2C9 inhibitorInhibitor0.5816
CYP450 2D6 inhibitorNon-inhibitor0.8059
CYP450 2C19 inhibitorInhibitor0.6604
CYP450 3A4 inhibitorInhibitor0.7409
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8396
Ames testNon AMES toxic0.6203
CarcinogenicityNon-carcinogens0.6871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6599 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9254
hERG inhibition (predictor II)Non-inhibitor0.6427
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Daiichi sankyo inc
  • Daiichi Sankyo
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral
TabletOral
TabletOral20 mg
TabletOral40 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Benicar 5 mg tablet12.81USD tablet
Benicar hct 40-25 mg tablet4.93USD tablet
Benicar hct 40-12.5 mg tablet4.67USD tablet
Benicar hct 20-12.5 mg tablet3.94USD tablet
Benicar 40 mg tablet3.74USD tablet
Benicar 20 mg tablet2.97USD tablet
Olmetec 20 mg Tablet1.04USD tablet
Olmetec 40 mg Tablet1.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2061607 No1999-01-192012-02-20Canada
US5616599 Yes1996-10-252016-10-25Us
US6878703 Yes2002-05-192022-05-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point175-180 °CNot Available
logP5.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP2.98ALOGPS
logP2.14ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)0.91ChemAxon
pKa (Strongest Basic)5.57ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.81 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.32 m3·mol-1ChemAxon
Polarizability47.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • 1,2,4,5-tetrasubstituted imidazole
  • Phenylmethylamine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary alcohol
  • Imidazole
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Koike H, Sada T, Mizuno M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001 Jun;19(1):S3-14. [PubMed:11451212 ]
  3. Ochiai K, Hu Q, Lee J, Mansoor A, Liu J, Wang X, Gong G, Murakami Y, Ishibashi Y, Shimada T, Zhang J: Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling. J Cardiovasc Pharmacol. 2006 May;47(5):686-94. [PubMed:16775509 ]
  4. Warner GT, Jarvis B: Olmesartan medoxomil. Drugs. 2002;62(9):1345-53; discussion 1354-6. [PubMed:12076183 ]
  5. Mire DE, Silfani TN, Pugsley MK: A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005 Nov;46(5):585-93. [PubMed:16220064 ]
  6. Kreutz R, Bolbrinker J, Huber M: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig. 2006;26(1):29-34. [PubMed:17163232 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
  2. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 11, 2016 03:56